---
title: "Why Halozyme, An IBD 50 Stock, Just Hit A Record High In Bullish Volume"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295253586.md"
description: "Halozyme's stock soared to an all-time high on Friday due to the increasing success of its newer products utilizing the Enhanze technology. This surge in stock value resulted in bullish trading volume. The company's stock performance has been notable, with it being identified as an IBD 50 stock."
datetime: "2026-08-07T15:00:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295253586.md)
  - [en](https://longbridge.com/en/news/295253586.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295253586.md)
---

# Why Halozyme, An IBD 50 Stock, Just Hit A Record High In Bullish Volume

Halozyme's stock soared to an all-time high on Friday due to the increasing success of its newer products utilizing the Enhanze technology. This surge in stock value resulted in bullish trading volume. The company's stock performance has been notable, with it being identified as an IBD 50 stock.

### Related Stocks

- [HALO.US](https://longbridge.com/en/quote/HALO.US.md)
- [FFTY.US](https://longbridge.com/en/quote/FFTY.US.md)

## Related News & Research

- [Halozyme CEO Helen Torley sells USD 4.13 million in common shares](https://longbridge.com/en/news/296412342.md)
- [Aurora Investment Counsel Takes Position in Halozyme Therapeutics, Inc. $HALO](https://longbridge.com/en/news/296450253.md)
- [Halozyme Buy Rating Reiterated as VYVGART Hytrulo Data Support Royalty Growth; $115 Price Target Unchanged](https://longbridge.com/en/news/296135927.md)
- [Huge Unusual Long-Dated Call Options in Oracle Corp - A Covered Call ORCL Play?](https://longbridge.com/en/news/296133482.md)
- [Insider Selling: Halozyme Therapeutics (NASDAQ:HALO) Director Sells $167,152.80 in Stock](https://longbridge.com/en/news/295589663.md)